Is peroxisome proliferation an obligatory precursor step in the carcinogenicity of di(2-ethylhexyl)phthalate (DEHP)? by Melnick, R L
Environmental Health Perspectives • VOLUME 109 | NUMBER 5 | May 2001 437
Is Peroxisome Proliferation an Obligatory Precursor Step in the
Carcinogenicity of Di(2-ethylhexyl)phthalate (DEHP)?
Ronald L. Melnick
National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
Di(2-ethylhexyl)phthalate (DEHP) has been
classified by the International Agency for
Research on Cancer (IARC) as possibly car-
cinogenic to humans (group 2B) (1) and by
the National Toxicology Program as reason-
ably anticipated to be carcinogenic to humans
(2). These listings are based on dosed feed
studies conducted by the National Toxicology
Program which demonstrated that DEHP
induced dose-related increases in liver tumors
in both sexes of rats and mice (3,4). No epi-
demiologic studies on DEHP carcinogenicity
have been reported.
The finding that DEHP was not muta-
genic in Salmonella, with or without meta-
bolic activation, but that it induced
hepatomegaly and hepatic peroxisome
proliferation in rats and mice and reduced
serum concentrations of cholesterol and
triglycerides, similar to clofibrate and other
hypolipidemic drugs, has stimulated extensive
research efforts aimed at understanding the
potential role of peroxisome proliferation in
hepatocarcinogenesis. In light of the develop-
ing mechanistic information on peroxisome
proliferation, some reviewing agencies have
been urged to reexamine their cancer classiﬁ-
cation for DEHP. For example, Doull et al.
(5) contend that “DEHP should be classiﬁed
as unlikely to be a human carcinogen under
any known conditions of human exposure,”
because “DEHP exerts its tumorigenic
response through the process of peroxisome
proliferation,” an effect to which “humans are
almost completely nonresponsive.” However,
while acknowledging that the mechanism of
rodent hepatocarcinogenesis of DEHP is not
fully understood, Doull et al. (5) claim that
“the hepatocarcinogenic effects of DEHP in
rodents result directly from the receptor-
mediated, threshold-based mechanism of per-
oxisome proliferation, a well understood
process associated uniquely with rodents.”
This view is based to a large extent on a
“strong concordance between peroxisome
proliferation and hepatocarcinogenesis in rats
and mice” (5) and the claimed “scientiﬁc con-
sensus that its [DEHP] hepatocarcinogenic
action in rodents is associated with peroxi-
some proliferation and increased hepatocyte
replication.”
Likewise, an IARC working group
recently downgraded DEHP to “not classiﬁ-
able as to its carcinogenicity to humans”
(group 3) because they concluded that
DEHP produces liver tumors in rats and
mice by a mechanism involving peroxisome
proliferation, which they judged to be not
relevant to humans (6). The term “respon-
sive” is used in this commentary to indicate
the induction of increased volume density of
peroxisomes and/or peroxisomal enzyme
activities in liver cells resulting from in vivo
or in vitro exposure to agents that have been
shown to induce these effects in rats and/or
mice. The main issue addressed in this com-
mentary is whether or not current scientiﬁc
data support the claim that the carcinogenic
effects of DEHP observed in rats and mice
result from peroxisome proliferation and
therefore do not represent a potential cancer
risk to humans. I evaluate this issue by
reviewing available data relevant to possible
mechanism(s) of carcinogenicity of DEHP
and other peroxisome proliferators and by
examining how that information might
impact our understanding of potential can-
cer risk from DEHP. In addition, a future
research direction is suggested for evaluating
potential biological effects of peroxisome
proliferators in rodent and human tissues.
Our knowledge of the mechanism of per-
oxisome proliferation has advanced greatly
over the past 10 years; however, the actual
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Di(2-ethylhexyl)phthalate (DEHP), a peroxisome proliferator, has been listed by the International
Agency for Research on Cancer (IARC) and by the National Toxicology Program as a possible or
reasonably anticipated human carcinogen because it induces dose-related increases in liver tumors
in both sexes of rats and mice. Recently, the suggestion has been advanced that DEHP should be
considered unlikely to be a human carcinogen because it is claimed that the carcinogenic effects of
this agent in rodents are due to peroxisome proliferation and that humans are nonresponsive to this
process. An IARC working group recently downgraded DEHP to “not classiﬁable as to its carcino-
genicity to humans” because they concluded that DEHP produces liver tumors in rats and mice by
a mechanism involving peroxisome proliferation, which they considered to be not relevant to
humans. The literature review presented in this commentary reveals that, although our knowledge
of the mechanism of peroxisome proliferation has advanced greatly over the past 10 years, our
understanding of the mechanism(s) of carcinogenicty of peroxisome proliferators remains incom-
plete. Most important is that published studies have not established peroxisome proliferation per
se as an obligatory pathway in the carcinogenicity of DEHP. No epidemiologic studies have been
reported on the potential carcinogenicity of DEHP, and cancer epidemiologic studies of hypolipi-
demic ﬁbrate drugs (peroxisome proliferators) are inconclusive. Most of the pleiotropic effects of
peroxisome proliferators are mediated by the peroxisome proliferator activated receptor (PPAR), a
ligand-activated transcription factor that is expressed at lower levels in humans than in rats and
mice. In spite of this species difference in PPAR expression, hypolipidemic fibrates have been
shown to induce hypolipidemia in humans and to modulate gene expression (e.g., genes regulating
lipid homeostasis) in human hepatocytes by PPAR activation. Thus, humans are responsive to
agents that induce peroxisome proliferation in rats and mice. Because peroxisome proliferators can
affect multiple signaling pathways by transcriptional activation of PPAR-regulated genes, it is
likely that alterations in speciﬁc regulated pathways (e.g., suppression of apoptosis, protooncogene
expression) are involved in tumor induction by peroxisome proliferators. In addition, because
DEHP also induces biological effects that occur independently of peroxisome proliferation (e.g.,
morphologic cell transformation and decreased levels of gap junction intercellular communication),
it is possible that some of these responses also contribute to the carcinogenicity of this chemical.
Last, species differences in tissue expression of PPARs indicate that it may not be appropriate to
expect exact site correspondence for potential PPAR-mediated effects induced by peroxisome pro-
liferators in animals and humans. Because peroxisome proliferation has not been established as an
obligatory step in the carcinogenicity of DEHP, the contention that DEHP poses no carcinogenic
risk to humans because of species differences in peroxisome proliferation should be viewed as an
unvalidated hypothesis. Key words: apoptosis, cell proliferation, di(2-ethylhexyl)phthalate,
hypolipidemic drugs, peroxisome proliferation, peroxisome proliferator activated receptor. Environ
Health Perspect 109:437–442 (2001). [Online 24 April 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p437-442melnick/abstract.html
Commentarymechanistic events involved in the carcino-
genicity of DEHP or other peroxisome prolif-
erators have not been adequately elucidated.
Consequently, current mechanistic data do
not rule out the possibility that DEHP poses
a cancer risk to humans by mechanisms inde-
pendent of peroxisome proliferation. 
What Is the Mechanistic Basis for
the Correlation between Peroxisome
Proliferation and Liver Cancer
Induction in Rats and Mice? 
Based on an apparent correlation between
peroxisome proliferation and hepatocarcino-
genesis, Reddy et al. (7) proposed that
hypolipidemic peroxisome proliferators may
represent a novel class of chemical carcino-
gens. This diverse group of chemicals,
including hypolipidemic ﬁbrate drugs, plas-
ticizers (e.g., DEHP), various pesticides, and
solvents, have been found to induce peroxi-
some proliferation and liver cancer in rats
and mice. Several peroxisome proliferators
also induce testicular neoplasms (8). 
An IARC working group that evaluated
the role of peroxisome proliferation in chemi-
cal carcinogenesis (9) acknowledged that the
mechanism of tumor induction by peroxi-
some proliferators is incomplete, but still
concluded that peroxisome proliferator-
induced liver cancer in rats and mice was
likely due to oxidative stress from peroxisome
proliferation and/or increased hepatocellular
proliferation. Because data on hypolipidemic
ﬁbrate drugs indicated little peroxisome pro-
liferation in human liver and no induction in
cultured human hepatocytes, the IARC
working group recommended that tumor
responses in rats or mice occurring secondary
to peroxisome proliferation could be dis-
counted in overall evaluations if a) informa-
tion is available to exclude mechanisms of
carcinogenesis other than those related to
peroxisome proliferation, b) peroxisome pro-
liferation and hepatocellular proliferation
were demonstrated under the conditions of
the bioassay, and c) such effects have not
been found in adequate human studies. For
DEHP, insufficient data are available to
establish criteria a and c, and regarding crite-
rion b, hepatocellular proliferation induced
by DEHP is not a sustained response with
continued exposure to this agent.
If peroxisome proliferation alone is pre-
dictive of liver cancer outcome, then similar
levels of peroxisome proliferation should
lead to similar incidences of liver tumors in
experimental animals. However, this is not
always the case. For example, at doses of
DEHP and Wy-14,643 that produce similar
levels of peroxisome proliferation in rat liver,
Wy-14,643 produced an earlier and much
greater liver tumor response than did DEHP
(10). Thus, peroxisome proliferation alone
does not provide an adequate mechanistic
explanation for the different carcinogenic
potencies of DEHP and WY-14,643 in the
rat liver. 
Although increased replicative DNA syn-
thesis and cell division have been suggested
as the mechanism of peroxisome prolifera-
tor-mediated carcinogenesis, persistent
increases in hepatocyte proliferation do not
occur with DEHP or most hypolipidemic
fibrate drugs. Except for Wy-14,643 (10),
cell replication rates return to control levels
within 10–30 days of continuous treatment.
Thus, the sustained increase in cell replica-
tion that has been seen with Wy-14,643
(10) does not apply to other peroxisome pro-
liferators (11). Although cell proliferation is
an integral component of chemical carcino-
genesis, scientific data do not substantiate
the hypothesis that induction of cancer by
nongenotoxic carcinogens occurs solely by a
transient increase in cell division (12). For
peroxisome proliferators, other reported
effects such as suppression of apoptosis (13),
inhibition of gap junction intercellular com-
munication (9), activation of Kupffer cells
(14), induced protooncogene expression
(15,16), or a combination of these factors
(e.g., disruption in the balance between
hepatocyte proliferation and apoptosis) (13)
may be involved in the carcinogenic process. 
Are Data from Studies in Humans or
Human Tissues on the Induction of
Peroxisome Proliferation and
Potential Carcinogenicity of
Peroxisomal Proliferators, Including
DEHP, Reliable for Assessing
Human Risk?
Because of the commercial value of many
agents that induce peroxisome proliferation,
research efforts have focused on the mecha-
nism of toxicity/carcinogenicity of these
chemicals with the goal of elucidating a
species-specific response. It has been often
claimed that humans are refractory to adverse
effects of peroxisome proliferators. This is
based on reports that chemicals (including
DEHP and its metabolites) that induce per-
oxisome proliferation in rat or mouse hepato-
cyte cultures do not induce peroxisome
proliferation in cultured human hepatocytes
(17,18), and that no increase in liver cancer
has been observed in studies of patients
treated with hypolipidemic ﬁbrate drugs. In
addition, induction of peroxisomal β -oxida-
tion and DNA synthesis and suppression of
apoptosis were observed in rat hepatocytes
incubated with nafenopin, mono(2-ethyl-
hexyl)phthalate (MEHP; the primary
metabolite of DEHP), or diisononylphtha-
late, but not in cultured human hepatocytes
(19–22).
Because of the public health implications
of the claims that humans are nonresponsive
to adverse effects of peroxisome proliferators,
it is necessary to evaluate the data used to
make these claims for adequacy and poten-
tial confounders. First, the fact that
hypolipidemia (one of the pleiotropic effects
of peroxisome proliferators in rodents) is also
induced by hypolipidemic fibrate drugs in
humans demonstrates that humans are
responsive to these agents. Second, a moder-
ate increase in peroxisome number or vol-
ume density was observed in liver biopsies
taken from patients treated with cloﬁbrate or
ciproﬁbrate (23). Third, Perrone et al. (24)
reported that two peroxisome proliferators,
clofibrate and ciprofibrate, induced a 2- to
3-fold increase in peroxisomal enzyme activ-
ity in cultured human hepatocytes. 
With respect to the relationship between
cell proliferation and tumor outcome, issues
such as whether the response is transient or
sustained and the speciﬁc population of cells
that are responsive need to be determined.
For example, cell culture studies cannot estab-
lish a sustained response, and the balance
between cell replication and cell loss in pre-
neoplastic hepatic foci may be more relevant
to the carcinogenic process for peroxisome
proliferators than measurements of cell prolif-
eration in normal hepatocytes (11,12,25).
The finding that 22 weeks of exposure to
WY-14,643 induced a greater carcinogenic
response in the liver of old rats (starting age
of 15 months of age) compared to young rats
(starting age of 2 months), but that peroxi-
some proliferation and sustained hepatocellu-
lar proliferation were not different in relation
to age, suggests that the greater accumulation
of spontaneously initiated foci in old rats
may be a critical factor in the carcinogenic
mechanism of this compound (25). Human
cell culture studies have focused mainly on
responses to peroxisome proliferators in nor-
mal hepatocytes, although some studies have
examined responses in the human HepG2
hepatoma cell line. 
With respect to their carcinogenic poten-
tial in humans, cancer epidemiologic studies
of hypolipidemic fibrate drugs are consid-
ered to be “of limited value because of the
short time periods involved” (23) or “incon-
clusive because of inconsistent results and
insufﬁcient duration of follow-up” (26). No
epidemiologic studies on the potential car-
cinogenicity of DEHP have been reported.
Thus, current epidemiologic data neither
demonstrate an increase in liver cancer in
patients treated with hypolipidemic drugs
nor do they support the assertion that
humans are resistant to the adverse effects of
DEHP or other peroxisome proliferators.
Several other important issues impact
evaluations of peroxisome proliferation in
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to receptor-mediated gene induction may
vary greatly among individuals due to differ-
ences in genetic factors, diet, lifestyle, health
status, and so on. Few studies use large
enough populations to evaluate potential
interindividual variability in response.
Second, because peroxisome proliferation is
a reversible process, evaluations of human
liver samples obtained several days after
exposure may not provide meaningful
results. Greater individual characterization of
exposure and other biological factors, includ-
ing those that might affect the pharmacoki-
netics of the receptor ligand, are needed for
evaluations of potential human responsive-
ness to peroxisome proliferators. In addition,
the quality of human liver samples used for
in vitro studies may vary substantially com-
pared to livers obtained from laboratory ani-
mals. Hepatocytes from rodent livers are
harvested immediately after death, whereas
several hours may elapse before harvesting
human hepatocytes. Cellular degradative
changes occurring during this time interval
may affect the responsiveness of human
hepatocyte cultures. Studies that do not eval-
uate functional responsiveness of human
hepatocyte preparations are of limited value
for assessing induction of peroxisome prolif-
eration. Several recent studies with human
hepatocyte cultures have used tumor growth
factor β 1 (TGFβ 1) to induce apoptosis and
epidermal growth factor as a positive control
for induction of DNA synthesis and sup-
pression of apoptosis (21). An additional
consideration is that tissue culture assays
may not be studying the appropriate cell
population with respect to cancer risk from
peroxisome proliferators. Future studies may
need to examine responses in preneoplastic
cells rather than responses only in normal
hepatocytes. Also, consideration should be
given to the possibility that conditions (e.g.,
timing and duration of exposure) that work
best for rodent hepatocytes may not be opti-
mal for human cells.
What Is the Mechanistic Basis for
Biological Effects Induced by DEHP
or Other Peroxisome Proliferators?
The discovery of the peroxisome proliferator
activated receptor (PPAR) (27), a ligand-
activated transcription factor, provides a
mechanistic basis for understanding how
peroxisome proliferators modulate gene
expression leading to the induction of perox-
isomal enzymes. Several PPAR subtypes have
been identified, with PPARα implicated in
hepatic responses. Binding of a peroxisome
proliferator (ligand) to PPARα activates this
nuclear hormone receptor. Ligand-bound
PPARα regulates gene transcription by form-
ing heterodimers with the retinoid X receptor,
RXR (28) (i.e., L-PPARα -RXR), which can
bind specifically to peroxisome proliferator
response elements (PPREs) in the promoter
region of peroxisome proliferator regulated
genes. This interaction leads to transcriptional
activation of these regulated genes, i.e., 
L− PPARα− RXR + regulated gene-PPRE →
regulated gene mRNA↑
resulting in increased hepatic DNA synthe-
sis, hepatomegaly, peroxisome proliferation,
and the induction of several peroxisomal and
microsomal enzymes. Suppression of hepato-
cyte apoptosis (programmed cell death) by
peroxisome proliferators is also mediated by
PPARα (29). The transcriptional effects of
activated PPARα may be further modulated
by interactions with other transcriptional
factors (coactivators or suppressors).
Human PPARs are responsive to MEHP,
the primary metabolite of DEHP. MEHP
has been shown to stimulate transcriptional
activation of human or mouse PPARα in
transfected COS-1 monkey kidney cells,
whereas DEHP was inactive (30). MEHP
also induced transcriptional activation of
human and mouse PPARγ . 
Transgenic mice lacking PPARα (PPARα
knock-out mice) do not elicit hepatic peroxi-
some proliferation, replicative DNA synthesis,
or liver enlargement with exposure to peroxi-
some proliferators (31). These mice also dis-
play abnormal lipid metabolism and show no
increase in liver tumor incidence after 11
months of feeding with Wy14,643 (32,33).
Thus, it was suggested (32,33) that peroxi-
some proliferation, hepatocyte replicative
DNA synthesis, hypolipidemia, and peroxi-
some proliferator-induced hepatocarcinogene-
sis are mediated by PPARα . However, no
2-year carcinogenicity studies have been
reported for peroxisome proliferators in
PPARα -null mice; such information is neces-
sary to evaluate the possible occurrence of
late-developing tumors arising by mechanisms
independent of PPARα . Studies in PPARα -
null mice compared to wild-type mice reﬂect
outcomes linked to gene expression pathways
modulated by this receptor. It is important to
note that this model does not represent
potential human responses to peroxisome
proliferators because, unlike humans,
PPARα -null mice lack a functional PPARα .
Are all biological effects of DEHP or its
metabolites mediated by PPARα ? Deﬁnitely
not. For example, oral administration of
DEHP to rats induced liver mitochondrial
swelling and reduced succinate dehydroge-
nase (SDH) activity (34), and studies with
isolated rat liver mitochondria showed that
MEHP caused uncoupling of oxidative phos-
phorylation and inhibition of SDH activity
(35). Whether these effects are related to a
cancer outcome is unknown; however, they
demonstrate that DEHP or its metabolites
can elicit biological effects in the liver that are
independent of PPARα . Further discussion
on extraperoxisomal effects of peroxisome
proliferators in laboratory animals and
humans can be found in a comprehensive
review by Youssef and Badr (36).
The induction of reproductive toxicity,
teratogenicity, and altered zinc metabolism by
DEHP in wild-type mice and in PPARα -null
mice indicates that these effects are not medi-
ated through PPARα -dependent mechanisms
(37). Ward et al. (38) found that toxic liver
lesions observed in wild-type mice fed DEHP
were not present in treated PPARα -null mice.
However, the PPARα -null mice did develop
delayed toxic lesions in the kidney (severe
nephropathy) and testis (tubular degeneration
and reduced spermatogenesis), indicating that
DEHP can induce renal and testicular toxic-
ity independent of PPARα . Whether these
effects are mediated by a different PPAR iso-
form is unknown.
In a study of morphologic transforma-
tion in Syrian hamster embryo (SHE) cells,
Tsutsui et al. (39) found that DEHP but not
cloﬁbrate induced morphologic transforma-
tion. Cell transformation by DEHP was
enhanced by metabolic activation, which
also resulted in chromosome aberrations.
Wy-14,643, a more potent carcinogen than
DEHP, was more active in inducing chro-
mosome aberrations. These results suggest
that chromosomal damage may contribute
to the carcinogenic activities of some peroxi-
some proliferators. DEHP increased the fre-
quency of morphologic transformation and
decreased the levels of gap junction intercel-
lular communication in SHE cells (40). The
induction of morphologic cell transforma-
tion, inhibition of gap-junction intercellular
communication, and activation of Kupffer
cells appear to be independent of peroxisome
proliferation (9,14) and may represent addi-
tional effects that contribute to the carcino-
genicity of certain peroxisome proliferators. 
What Is the Basis for Species
Differences in Responses Mediated
by PPARα ?
Humans and guinea pigs have been labeled as
nonresponsive species even though they
express a functionally active PPARα
(30,41–44). The lack of response of human
hepatocyte cultures has been attributed to low
levels of PPARα expression in human liver
(45). Human liver samples were reported to
have 10-fold lower levels of PPARα mRNA
than mouse liver (43). However, comparisons
of mRNA levels across species may not accu-
rately represent equivalent differences in
PPARα protein levels because of possible 
differences in rates of translation of message
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specific mRNA and protein products. In
addition, because human RNA was generally
obtained from liver samples that were frozen
several hours after death, the reported low lev-
els of PPARα mRNA and protein in human
liver may in part reflect losses occurring
before the samples were frozen. PPARα
mRNA and the corresponding functional
protein (i.e., the protein that mediates tran-
scriptional activation through PPRE) are also
expressed in guinea pig liver, but at much
lower levels than in mice (46,47). The level of
liver PPARα mRNA in humans was reported
to be approximately 10% of that in mice,
20% of that in rats, and two times higher
than that in guinea pigs (46). PPARα s from
all of these species had similar binding afﬁni-
ties for rat acyl CoA oxidase (ACO) PPRE
and comparable activities in reporter gene
assays, indicating their functional similarity.
A human peroxisomal ACO promoter
gene was cloned and found to be responsive
to peroxisome proliferators in reporter gene
assays (48); in contrast, a follow-up study
found the human ACO gene promoter to be
inactive in a sample human population (49).
The lack of induction of peroxisomal ACO
activity in this group was suggested to be
due to an inactive PPRE sequence in the
ACO gene promoter rather than to lower
cellular concentrations of PPARα (49). In
line with this suggestion, it is important to
note that there are no data on whether, or to
what extent (i.e., population distribution),
inactive PPRE sequences exist in the pro-
moter region of genes that directly impact
the potential carcinogenicity of peroxisome
proliferators in humans. 
Is Peroxisome Proliferation an
Obligatory Step for Tumor Induction
by DEHP and Other Peroxisome
Proliferators?
Several investigators of peroxisome prolifer-
ator induced responses acknowledge uncer-
tainty on whether or how PPARα might
influence the possible carcinogenicity of
peroxisome proliferators in humans; this is
because the mechanism(s) of carcinogenic-
ity of these agents are not understood
(31,38,41,43). Although it is well estab-
lished that peroxisome proliferators alter
gene expression by a receptor-mediated
process, the molecular mechanisms of mod-
ulation of cell proliferation and suppression
of apoptosis by peroxisome proliferators are
not known (13). Furthermore, the sustain-
ability of growth perturbation responses
(mitogenesis and apoptosis) have not been
fully described for any species, and the
extent to which such effects occur in
human preneoplastic cells has not been
determined.
Current data are insufficient to answer
the question of whether tumorigenesis by
DEHP or other peroxisome proliferators is
restricted to rats and mice. There are no car-
cinogenicity data on DEHP or other peroxi-
some proliferators in any other animal
species, including those that express low lev-
els of PPARα (e.g., guinea pig). In addition,
there are no cancer epidemiology studies on
DEHP, and human studies on hypolipi-
demic fibrate drugs are inconclusive.
Furthermore, the potential role of nonrecep-
tor-mediated effects of DEHP and other
peroxisome proliferators in human popula-
tions have not been evaluated. Because per-
oxisome proliferation is one of several
changes produced by DEHP, it is not possi-
ble to conclude that peroxisome prolifera-
tion alone is the cause of liver cancers
induced in rats and mice. 
As in humans, fibrate drugs induce
hypolipidemia in guinea pigs in spite of the
low expression of PPARα . In addition, perox-
isome proliferators did not induce replicative
DNA synthesis or peroxisome proliferation in
primary cultures of guinea pig hepatocytes,
although apoptosis was markedly suppressed
by a PPARα mediated mechanism (19,46).
Thus, suppression of apoptosis appears to be
regulated independently from induction of
DNA synthesis. Suppression of apoptosis by
peroxisome proliferators could prevent the
death and removal of preneoplastic cells with
damaged DNA and thereby contribute to the
carcinogenic process. Because peroxisome
proliferators induce suppression of apoptosis
in guinea pig hepatocytes without inducing
peroxisomal enzymes, it is apparent that cer-
tain PPARα regulated pathways are respon-
sive even in species with low levels of PPARα
expression. Measurements of apoptosis in
human hepatocyte cultures have given mixed
results. Hasmall et al. (20,21) reported no
effect of nafenopin or MEHP on apoptosis in
human hepatocytes, whereas Perrone et al.
(24) observed an increase in spontaneous
apoptosis in human hepatocytes incubated
with clofibric acid or ciprofibrate. Results
from the later study also showed a signiﬁcant
trend for suppression of apoptosis by ciproﬁ-
brate in human hepatocytes incubated for 24
hr in the presence of TGFβ , with a marginal
response at the higher dose.
The pleiotropic effects of peroxisome pro-
liferators are dependent on the existence of
functional PPARs and PPREs in the pro-
moter regions of genes regulated by these
agents. Activation of PPARα modulates lipid
homeostasis in humans (50), by the same
receptor-mediated process as that which
induces peroxisome proliferation in the
rodent liver. Vu-Dac et al. (51) showed that
fenoﬁbrate induced a 2.5- to 4.5-fold increase
in apolipoprotein A-II mRNA in human
hepatocytes consequent to PPAR binding to
the AII-PPRE. These results demonstrate that
fibrates can modulate gene expression in
humans by PPAR activation, whether or not
peroxisomal enzymes are induced. 
The critical steps in peroxisome prolifer-
ator-induced carcinogenesis need to be eluci-
dated before it is possible to attribute a
particular gene expression pathway (i.e., per-
oxisomal enzymes) as the cause of tumor
induction. The contention that peroxisome
proliferation and PPARα expression levels
reflect species-specific susceptibility to the
carcinogenic effects of peroxisome prolifera-
tors is an oversimpliﬁcation of complex sig-
naling mechanisms; nonresponsive species
clearly elicit responses to peroxisome prolif-
erators that are mediated by PPARα (e.g.,
suppression of apoptosis, hypolipidemic
effects). A correlation between peroxisome
induction and tumor development in rats
and mice may reﬂect a coincidental observa-
tion rather than a causal relationship.
Because peroxisome proliferators can affect
multiple signaling pathways by transcrip-
tional activation of PPAR-regulated genes, it
is possible that chemicals such as DEHP
contribute to the cancer process by mecha-
nisms independent of peroxisomal prolifera-
tion or mitogenesis (e.g., suppression of the
apoptotic removal of initiated cells). 
If tumor induction by peroxisome prolif-
erators is mediated by PPARα , then it may
not be appropriate to expect exact site corre-
spondence in animals and humans. The tissue
distribution of PPARα is different in humans
than it is in rats or mice (43). In humans, the
highest levels of PPARα mRNA are in skele-
tal muscle and kidney, and low levels were
found in the liver. In rats and mice the high-
est levels of PPARα expression are in the liver
and kidney, yet peroxisome proliferators do
not appear to cause tumors of the kidney. 
The ﬁnding of PPARα mRNA and pro-
tein in rat and adult human testes suggests
that this receptor may be involved in regulat-
ing the growth of tubular and interstitial
cells in the testis of rats and humans (52).
The demonstration of a functional PPAR in
human breast cancer cell lines that can bind
speciﬁcally to a PPRE indicates that peroxi-
some proliferators may transcriptionally acti-
vate peroxisome proliferator-regulated genes
in human breast epithelial cells (53).
Furthermore, stimulation of cell prolifera-
tion by DEHP in a human breast cancer cell
line has been observed (54); however, the
mechanism of this response has not been
elucidated. The potential for peroxisome
proliferators to affect human breast cancer
risk has not been determined.
It is not known if there is a differential
human sensitivity to the effects of peroxi-
some proliferators or whether there are highly
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tions. In a study of 10 individual liver sam-
ples, PPARα mRNA levels differed by
approximately 10-fold (43). Interindividual
variability in PPARα base sequences along
with possible variable levels of induced
PPARα expression by glucocorticoids or
nutritional factors may render certain indi-
viduals more responsive to peroxisome prolif-
erators than the general population (55). 
Conclusions and Future
Research Needs
Although our understanding of the mecha-
nism(s) of peroxisome proliferation and
induction of peroxisomal ACO activity has
advanced immensely over the past 10 years,
there is still insufﬁcient data to conclude that
DEHP poses no cancer risk to humans. The
fact that peroxisome proliferators have been
shown to modulate gene expression in
human hepatocytes (expression of genes reg-
ulating lipid homeostasis) and in guinea pig
hepatocytes (suppression of apoptosis)
through the activation of PPARα without
inducing peroxisomal enzymes raises the dis-
tinct possibility that transcriptional activa-
tion of PPAR-responsive genes associated
with the carcinogenic process can occur
independently of peroxisome proliferation.
Even in rodent liver cells, differences in
dose–response relationships among the
pleotropic effects of peroxisome proliferators
(22) suggest that although these processes
may be dependent on PPAR activation, they
likely occur by independent mechanisms.
Further, due to differences in tissue distribu-
tion of PPARs in rodents and humans, it
may not be appropriate to expect responses
to peroxisome proliferators to exhibit site
correspondence across species. Issues raised
in this commentary cannot be resolved until
current hypotheses related to potential asso-
ciations between oxidative damage, pertur-
bation of growth control (enhancement of
cell proliferation and suppression of apopo-
tosis), and the carcinogenicity of DEHP and
other peroxisome proliferators are rigorously
tested and the mechanistic links between
these events are elucidated. 
DNA microarray technology could pro-
vide a powerful approach to resolve some of
the issues raised here. This technique uses
cDNA microarrays to simultaneously moni-
tor the expression of thousands of specified
genes. Speciﬁcally, a study is needed to quan-
tify time- and dose-dependent changes in
gene expression and consequent protein pro-
files resulting from exposure of freshly pre-
pared human hepatocytes (and preneoplastic
cells) to MEHP or other peroxisome prolifer-
ators. To determine whether and/or to what
extent these agents alter the expression of
protooncogenes, tumor-suppressor genes, or
other genes that regulate mitogenesis or apop-
tosis, tissue samples from a diverse population
of individuals need to be analyzed. Critical to
these evaluations would be the demonstration
of apolipoprotein A-II induction, conﬁrming
the functional responsiveness of human cell
cultures. Without this critical positive control,
it would not be possible to decipher the
absence of an effect as being due to the lack of
transcriptional function in human cell cul-
tures rather than lack of responsiveness to
these peroxisome proliferators.
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